GRCE Grace Therapeutics, Inc.

NASDAQ
$1.72

Grace Therapeutics, Inc. (GRCE) is expected to report earnings on February 11, 2027, before the market open. The stock has had a Post-Earnings Announcement Drift (PEAD) of -6.5% since its last earnings release on November 12, 2026.

Grace Therapeutics Reported Earnings
Thursday, November 12, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Dec 2026
Feb 11
Thursday · 8:00 AM ET
Earnings Whisper
-
vs -
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.75

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Grace Therapeutics, Inc.

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.